VERAXA Biotech (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026 in San Diego.
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results suggest potential for reducing off-target toxicities common with conventional ADCs.
VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other antibody-based formats.
The announcement comes as VERAXA prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026, a key industry event where the company hopes to advance its platforms through strategic collaborations. VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
For industry leaders, this news underscores the ongoing evolution of cancer therapeutics toward greater precision. If VERAXA’s BiTAC-ADC platform successfully translates to clinical settings, it could address a critical limitation of current ADCs: systemic toxicity due to premature drug release. The ability to spare healthy cells while destroying tumor spheroids in vitro suggests a potential for improved therapeutic indices, which could benefit patients and reduce healthcare costs associated with managing side effects.
However, the platform remains in early development, and investors and partners should exercise caution. The company’s forward-looking statements highlight risks inherent in drug development, including uncertainties in clinical translation and regulatory approval. The data presented are from in vitro studies, and further validation in animal models and human trials is required.
VERAXA’s diversified pipeline, including T-cell engagers, positions it to address multiple cancer types through different mechanisms. For the biotechnology sector, the company’s approach exemplifies the trend toward conditional activation of biologics, a strategy being pursued by other firms in the immuno-oncology space. The BIO Convention will be a critical venue for VERAXA to secure partnerships that can provide the resources and expertise needed to advance its platforms.
More information about the company, including the full press release, is available in VERAXA’s newsroom at https://ibn.fm/VRXA. Forward-looking statements and risk factors are detailed in the company’s SEC filings.
